Clinical trials: Attention Deficit With Hyperactivity Disorder
- Condition Attention Deficit With Hyperactivity Disorder
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder
A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
The purpose of the study is to investigate the clinical benefit of switching children with ADHD from immediate-release methylphenidate (IR-MPH) to OROS-methylphenidate under the correct dosage conversion scheme.
- Trial name
- NCT00518232
- Testing
- OROS-methylphenidate
- Volunteers
- 520 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.
2-week open-label safety, tolerability and pharmacokinetic study of methylphenidate HCl ERCT in 4-5 year old children with ADHD.
- Trial name
- NCT03546400
- Testing
- methylphenidate HCl ERCT
- Sponsor
- Pfizer
ADHD - Attention Deficit Disorder With Hyperactivity
Brain Stimulation and Attention Control in Children With ADHD
The goal of this clinical trial is to learn if brain stimulation can help children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) improve their attention and self-control.
- Trial name
- NCT07182344
- Testing
- Intermittent Theta Burst Stimulation to Right DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus
Stroke, Attention Disorder
Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury
Stroke is the leading cause of long-term disability with an increasing incidence, especially in young adults. Among the cognitive difficulties following brain damage, deficits in attention are frequent and pervasive, affecting…
- Trial name
- NCT05728840
- Testing
- Immersive virtual reality gamified cognitive activities, Double neuropsychological standard activities
- Where
- Switzerland
- Volunteers
- 135 people
- Sponsor
- Mindmaze SA
Attention-Deficit/Hyperactivity Disorder
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.
- Trial name
- PK003 (NCT02470234)
- Testing
- Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
Online Neuroplasticity Training for Remediation of ADHD in Adolescent Children (ONTRAC)
This project shall rigorously evaluate the effectiveness of a novel, neuroplasticity-based internet-deliverable cognitive training program, which specifically targets the treatment of core cognitive dysfunctions observed in…
- Trial name
- NCT01772485
- Testing
- Cognitive Training, Active Control
- Where
- India
- Volunteers
- 31 people
- Sponsor
- Posit Science Corporation
Attention Deficit Hyperactivity Disorder
Therapeutic Gaming for the Treatment of Attention Deficit Hyperactivity Disorder
Children with ADHD play a videogame to test symptom control
- Trial name
- THERAGAME (NCT05067322)
- Testing
- Minecraft
- Volunteers
- 2 people
- Sponsor
- Spherix Incorporated
Attention-Deficit/Hyperactivity Disorder
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
- Trial name
- NCT02736656
- Testing
- SPN-812
- Where
- 16 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
- Trial name
- NCT02083783
- Testing
- TRI102
- Where
- 5 sites in United States
- Volunteers
- 108 people
- Sponsor
- Tris Pharma, Inc.
Attention Deficit Disorder With Hyperactivity
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00246220
- Testing
- methylphenidate hydrochloride
- Volunteers
- 402 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Attention Deficit Hyperactivity Disorder, Healthy
The Effects of EPA/DHA Supplementation on Cognitive Control in Children With ADHD
Forty children with and 40 children without Attention deficit Hyperactivity Disorder (ADHD) receive Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) or placebo via a dietary intervention.
- Trial name
- NCT01554462
- Testing
- Eicosapentaenoic acid / Docosahexaenoic acid
- Where
- Netherlands
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Attention Deficit Disorder With Hyperactivity
Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD
- Trial name
- NCT00466791
- Testing
- Methylphenidate Transdermal System
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00783835
- Testing
- Long-Acting Methylphenidate
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Attention Deficit Hyperactivity Disorder
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.
- Trial name
- NCT07169162
- Testing
- ADZENYS XR-ODT
- Where
- United States
- Sponsor
- Aytu BioPharma, Inc.
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom…
- Trial name
- NCT03649074
- Testing
- AKL-T01
- Where
- 2 sites in United States
- Volunteers
- 206 people
- Sponsor
- Akili Interactive Labs, Inc.
ADHD
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).
- Trial name
- NCT00764868
- Testing
- Lisdexamfetamine Dimesylate (LDX)
- Where
- 45 sites in United States
- Volunteers
- 269 people
- Sponsor
- Shire
Attention-deficit Hyperactivity Disorder (ADHD)
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
This trial is a Phase 1 study in adolescents with ADHD and genetic disruptions impacting genes in the metabotropic glutamate receptor (mGluR) network.
- Trial name
- NFC1-GREAT (NCT02286817)
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
The aim of the iSPOT-A study is to: 1. identify brain, genetic and cognitive markers of Attention Deficit/Hyperactivity Disorder, and 2.
- Trial name
- NCT00863499
- Testing
- Short Acting Methylphenidate, Long Acting Methylphenidate
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 1,344 people, healthy volunteers welcome
- Sponsor
- BRC Operations Pty. Ltd.
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
ADHD
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an…
- Trial name
- NCT00228540
- Testing
- Modafinil
- Where
- 39 sites in United States
- Sponsor
- Cephalon